ReviewFrontiers in medicine2022
Aerosol delivery through high-flow nasal therapy: Technical issues and clinical benefits.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06815679 (The Physiological Effects of Nebulized Salbutamol in Patients With Acute Respiratory Failure During HFNC), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Physiological Effects of Nebulized Salbutamol in Patients With Acute Respiratory Failure During HFNC
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Aerosolized antifungal therapy in pulmonary fungal disease: pharmacology, drug delivery and emerging clinical applications.Frontiers in medicine · 2026Review
- High-flow nasal cannula in severe asthma exacerbations: current evidence and clinical perspectives.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Use of high flow nasal cannula in critical burn patient during deep sedation in enzymatic bromelain debridement (nexobridAnnals of burns and fire disasters · 2024Article
- Noninvasive Respiratory Support in Pediatric Critical Asthma: What to Start and Where to Go?Respiratory care · 2024Article
- Noninvasive Respiratory Support for Pediatric Critical Asthma: A Multicenter Cohort Study.Respiratory care · 2024Article
- Performance Characterisation of the Airvo2Pharmaceutics · 2024Article
- In Vivo Deposition of High-Flow Nasal Aerosols Using Breath-Enhanced Nebulization.Pharmaceutics · 2024Article
- Towards More Precise Targeting of Inhaled Aerosols to Different Areas of the Respiratory System.Pharmaceutics · 2024Review
- In-Line Aerosol Therapy via Nasal Cannula during Adult and Paediatric Normal, Obstructive, and Restrictive Breathing.Pharmaceutics · 2023Article
- Innovation in Drug Delivery Through High-Flow Nasal Cannula Systems and Its Evaluation.Respiratory care · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-flow nasal cannula (HFNC) therapy is an oxygen delivery method particularly used in patients affected by hypoxemic respiratory failure. In comparison with the conventional "low flow" oxygen delivery systems, it showed several important clinical benefits. The possibility to nebulize drugs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.